{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:47:47Z","timestamp":1792219667487,"version":"4.4.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s11033-022-07822-2","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T05:03:31Z","timestamp":1662959011000},"page":"11169-11176","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Nitazoxanide and COVID-19: A review"],"prefix":"10.1007","volume":"49","author":[{"given":"Hayder M.","family":"Al-kuraishy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali I.","family":"Al-Gareeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8287-1026","authenticated-orcid":false,"given":"Engy","family":"Elekhnawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaber El-Saber","family":"Batiha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"key":"7822_CR1","doi-asserted-by":"publisher","first-page":"642181","DOI":"10.3389\/fcvm.2021.642181","volume":"8","author":"HM Al-Kuraishy","year":"2021","unstructured":"Al-Kuraishy HM et al (2021) Case report: hyperbilirubinemia in Gilbert Syndrome attenuates Covid-19-induced metabolic disturbances. Front Cardiovasc Med 8:642181","journal-title":"Front Cardiovasc Med"},{"key":"7822_CR2","doi-asserted-by":"publisher","first-page":"104851","DOI":"10.1016\/j.antiviral.2020.104851","volume":"180","author":"D Tilmanis","year":"2020","unstructured":"Tilmanis D et al (2020) Host-targeted nitazoxanide has a high barrier to resistance but does not reduce the emergence or proliferation of oseltamivir-resistant influenza viruses in vitro or in vivo when used in combination with oseltamivir. Antiviral Res 180:104851","journal-title":"Antiviral Res"},{"issue":"6","key":"7822_CR3","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/hep4.1339","volume":"3","author":"JF Rossignol","year":"2019","unstructured":"Rossignol JF, Br\u00e9chot C (2019) A pilot clinical trial of nitazoxanide in the treatment of chronic hepatitis B. Hepatol Commun 3(6):744\u2013747","journal-title":"Hepatol Commun"},{"issue":"8","key":"7822_CR4","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1086\/428839","volume":"40","author":"LM Fox","year":"2005","unstructured":"Fox LM, Saravolatz LD (2005) Nitazoxanide: a new thiazolide antiparasitic agent. Clin Infect Dis 40(8):1173\u20131180","journal-title":"Clin Infect Dis"},{"issue":"10","key":"7822_CR5","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1128\/AAC.40.10.2266","volume":"40","author":"L Dubreuil","year":"1996","unstructured":"Dubreuil L et al (1996) In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Antimicrob Agents Chemother 40(10):2266\u20132270","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"7822_CR6","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1021\/acs.molpharmaceut.6b01089","volume":"14","author":"A Gupta","year":"2017","unstructured":"Gupta A et al (2017) Pharmacokinetics, metabolism, and partial biodistribution of \u201cpincer therapeutic\u201d nitazoxanide in mice following pulmonary delivery of inhalable particles. Mol Pharm 14(4):1204\u20131211","journal-title":"Mol Pharm"},{"issue":"8","key":"7822_CR7","doi-asserted-by":"publisher","first-page":"387","DOI":"10.5414\/CPP38387","volume":"38","author":"J Broekhuysen","year":"2000","unstructured":"Broekhuysen J et al (2000) Nitazoxanide: pharmacokinetics and metabolism in man. Int J Clin Pharmacol Ther 38(8):387\u2013394","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"3","key":"7822_CR8","first-page":"192","volume":"7","author":"M Khatri","year":"2020","unstructured":"Khatri M, Mago P (2020) Nitazoxanide\/Camostat combination for COVID-19: an unexplored potential therapy. Chem Biol Lett 7(3):192\u2013196","journal-title":"Chem Biol Lett"},{"key":"7822_CR9","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.antiviral.2017.10.002","volume":"147","author":"D Tilmanis","year":"2017","unstructured":"Tilmanis D et al (2017) The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide. Antiviral Res 147:142\u2013148","journal-title":"Antiviral Res"},{"key":"7822_CR10","unstructured":"Belardo, G., et al. Nitazoxanide, a novel potential anti-influenza drug, acting in synergism with neuraminidase inhibitors. in 49th Annual Meeting of the Infectious Diseases Society of America. Boston, MA: Infectious Diseases Society of America. 2011."},{"issue":"1","key":"7822_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1743-422X-11-10","volume":"11","author":"Z Shi","year":"2014","unstructured":"Shi Z et al (2014) Nitazoxanide inhibits the replication of Japanese encephalitis virus in cultured cells and in a mouse model. Virol j 11(1):1\u201310","journal-title":"Virol j"},{"issue":"382","key":"7822_CR12","doi-asserted-by":"publisher","first-page":"eaaf9194","DOI":"10.1126\/scitranslmed.aaf9194","volume":"9","author":"S Athale","year":"2017","unstructured":"Athale S et al (2017) Influenza vaccines differentially regulate the interferon response in human dendritic cell subsets. Sci Transl Med 9(382):eaaf9194","journal-title":"Sci Transl Med"},{"issue":"11","key":"7822_CR13","doi-asserted-by":"publisher","first-page":"e00707","DOI":"10.1128\/AAC.00707-18","volume":"62","author":"W Dang","year":"2018","unstructured":"Dang W et al (2018) Nitazoxanide inhibits human norovirus replication and synergizes with ribavirin by activation of cellular antiviral response. Antimicrob Agents Chemother 62(11):e00707-e718","journal-title":"Antimicrob Agents Chemother"},{"key":"7822_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009182.pub2","author":"K Nikolova","year":"2014","unstructured":"Nikolova K et al (2014) Nitazoxanide for chronic hepatitis C. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD009182.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"7822_CR15","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.antiviral.2014.07.014","volume":"110","author":"J-F Rossignol","year":"2014","unstructured":"Rossignol J-F (2014) Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res 110:94\u2013103","journal-title":"Antiviral Res"},{"issue":"6","key":"7822_CR16","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1021\/acsinfecdis.0c00478","volume":"7","author":"AV Stachulski","year":"2020","unstructured":"Stachulski AV et al (2020) Therapeutic potential of nitazoxanide: an appropriate choice for repurposing versus SARS-CoV-2? ACS Infect Dis 7(6):1317\u20131331","journal-title":"ACS Infect Dis"},{"key":"7822_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.855496","author":"L Tian","year":"2022","unstructured":"Tian L et al (2022) Molnupiravir and its antiviral activity against COVID-19. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2022.855496","journal-title":"Front Immunol"},{"issue":"8","key":"7822_CR18","doi-asserted-by":"publisher","first-page":"851","DOI":"10.4155\/fmc-2017-0217","volume":"10","author":"AV Stachulski","year":"2018","unstructured":"Stachulski AV et al (2018) Second-generation nitazoxanide derivatives: thiazolides are effective inhibitors of the influenza a virus. Future Med Chem 10(8):851\u2013862","journal-title":"Future Med Chem"},{"key":"7822_CR19","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.3389\/fimmu.2018.01547","volume":"9","author":"T-F Yip","year":"2018","unstructured":"Yip T-F et al (2018) Advancements in host-based interventions for influenza treatment. Front Immunol 9:1547","journal-title":"Front Immunol"},{"issue":"1","key":"7822_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s43042-022-00252-6","volume":"23","author":"E Elekhnawy","year":"2022","unstructured":"Elekhnawy E, Negm WA (2022) The potential application of probiotics for the prevention and treatment of COVID-19. Egypt J Med Hum Genet 23(1):1\u20139","journal-title":"Egypt J Med Hum Genet"},{"key":"7822_CR21","doi-asserted-by":"publisher","first-page":"571553","DOI":"10.3389\/fmicb.2020.571553","volume":"11","author":"P Bhattacharyya","year":"2020","unstructured":"Bhattacharyya P, Biswas SC (2020) Small non-coding RNAs: do they encode answers for controlling SARS-CoV-2 in the future? Front Microbiol 11:571553","journal-title":"Front Microbiol"},{"key":"7822_CR22","doi-asserted-by":"crossref","unstructured":"Al-kuraishy HM et al (2021) Brain and peripheral neuronal injury in Covid-19: the panorama and dispute. 8(1):1\u20133","DOI":"10.47363\/AMR\/2021(8)194"},{"issue":"3","key":"7822_CR23","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jiph.2016.04.001","volume":"9","author":"J-F Rossignol","year":"2016","unstructured":"Rossignol J-F (2016) Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. J Infect Public Health 9(3):227\u2013230","journal-title":"J Infect Public Health"},{"issue":"12","key":"7822_CR24","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.3390\/ph14121313","volume":"14","author":"NG Attallah","year":"2021","unstructured":"Attallah NG et al (2021) Promising antiviral activity of agrimonia pilosa phytochemicals against severe acute respiratory syndrome coronavirus 2 supported with in vivo mice study. Pharmaceuticals 14(12):1313","journal-title":"Pharmaceuticals"},{"issue":"1","key":"7822_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s43094-020-00150-x","volume":"7","author":"E Elekhnawy","year":"2021","unstructured":"Elekhnawy E, Kamar AA, Sonbol F (2021) Present and future treatment strategies for coronavirus disease 2019. Future J Pharm Sci 7(1):1\u20139","journal-title":"Future J Pharm Sci"},{"key":"7822_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.628370","author":"H Zhou","year":"2021","unstructured":"Zhou H et al (2021) A review of SARS-CoV2: compared with SARS-CoV and MERS-CoV. Front Med. https:\/\/doi.org\/10.3389\/fmed.2021.628370","journal-title":"Front Med"},{"issue":"2","key":"7822_CR27","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3390\/v12020244","volume":"12","author":"J Xu","year":"2020","unstructured":"Xu J et al (2020) Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARS-CoV. Viruses 12(2):244","journal-title":"Viruses"},{"issue":"3","key":"7822_CR28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.4103\/bbrj.bbrj_103_20","volume":"4","author":"HM Al-Kuraishy","year":"2020","unstructured":"Al-Kuraishy HM et al (2020) Macrolides and COVID-19: an optimum premise. Biomed Biotechnol Res J (BBRJ) 4(3):189","journal-title":"Biomed Biotechnol Res J (BBRJ)"},{"issue":"5","key":"7822_CR29","first-page":"e02304","volume":"95","author":"HT Nguyen","year":"2020","unstructured":"Nguyen HT et al (2020) Spike glycoprotein and host cell determinants of SARS-CoV-2 entry and cytopathic effects. J Virol 95(5):e02304-e2320","journal-title":"J Virol"},{"key":"7822_CR30","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.3389\/fimmu.2020.01518","volume":"11","author":"TL Freeman","year":"2020","unstructured":"Freeman TL, Swartz TH (2020) Targeting the NLRP3 inflammasome in severe COVID-19. Front Immunol 11:1518","journal-title":"Front Immunol"},{"issue":"6504","key":"7822_CR31","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1126\/science.abc6027","volume":"369","author":"J Hadjadj","year":"2020","unstructured":"Hadjadj J et al (2020) Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 369(6504):718\u2013724","journal-title":"Science"},{"key":"7822_CR32","doi-asserted-by":"publisher","first-page":"104799","DOI":"10.1016\/j.micpath.2021.104799","volume":"153","author":"D Darif","year":"2021","unstructured":"Darif D et al (2021) The pro-inflammatory cytokines in COVID-19 pathogenesis: what goes wrong? Microb Pathog 153:104799","journal-title":"Microb Pathog"},{"issue":"1","key":"7822_CR33","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/jmv.26232","volume":"93","author":"B Hu","year":"2021","unstructured":"Hu B, Huang S, Yin L (2021) The cytokine storm and COVID-19. J Med Virol 93(1):250\u2013256","journal-title":"J Med Virol"},{"issue":"1","key":"7822_CR34","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1080\/07391102.2020.1814870","volume":"40","author":"RJ Khan","year":"2022","unstructured":"Khan RJ et al (2022) Identification of promising antiviral drug candidates against non-structural protein 15 (NSP15) from SARS-CoV-2: an in silico assisted drug-repurposing study. J Biomol Struct Dyn 40(1):438\u2013448","journal-title":"J Biomol Struct Dyn"},{"issue":"5","key":"7822_CR35","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1002\/jmv.26880","volume":"93","author":"H Elalfy","year":"2021","unstructured":"Elalfy H et al (2021) Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS. NRIZ study) on the clearance of mild COVID-19. J Med Virol 93(5):3176\u20133183","journal-title":"J Med Virol"},{"key":"7822_CR36","doi-asserted-by":"publisher","first-page":"155115","DOI":"10.1016\/j.cyto.2020.155115","volume":"131","author":"F Antony","year":"2020","unstructured":"Antony F et al (2020) Therapeutic potential of Nitazoxanide against Newcastle disease virus: a possible modulation of host cytokines. Cytokine 131:155115","journal-title":"Cytokine"},{"key":"7822_CR37","doi-asserted-by":"crossref","unstructured":"Miner K, Labitzke K, Liu B, Wang P, Henckels K, Gaida K, Elliott R, Chen JJ, Liu L, Leith A, Trueblood E, Hensley K, Xia XZ, Homann O, Bennett B, Fiorino M, Whoriskey J, Yu G, Escobar S, Wong M, Born TL, Budelsky A, Comeau M, Smith D, Phillips J, Johnston JA, McGivern JG, Weikl K, Powers D, Kunzelmann K, Mohn D, Hochheimer A, Sullivan JK (2019) Drug repurposing: the anthelmintics niclosamide and nitazoxanide are potent TMEM16A antagonists that fully bronchodilate airways. Front Pharmacol 14(10):51","DOI":"10.3389\/fphar.2019.00051"},{"key":"7822_CR38","doi-asserted-by":"publisher","unstructured":"Cadegiani FA et al (2020) Hydroxychloroquine, nitazoxanide and ivermectin have similar effects in early COVID-19: a head-to-head comparison of the Pre-AndroCoV Trial. https:\/\/doi.org\/10.21203\/rs.3.rs-100994\/v1","DOI":"10.21203\/rs.3.rs-100994\/v1"},{"key":"7822_CR39","unstructured":"Batiha GE, Shaheen HM, Al-Kuraishy HM, Teibo JO, Akinfe OA, Al-Garbee AI, Teibo TKA, Kabrah SM (2021) Possible\nmechanistic insights into iron homeostasis role of the action of 4-aminoquinolines (chloroquine\/hydroxychloroquine) on COVID-19 (SARS-CoV-2) infection. Eur Rev Med Pharmacol Sci 25(23):7565\u20137584"},{"key":"7822_CR40","doi-asserted-by":"publisher","first-page":"104874","DOI":"10.1016\/j.phrs.2020.104874","volume":"157","author":"MT Kelleni","year":"2020","unstructured":"Kelleni MT (2020) Nitazoxanide\/azithromycin combination for COVID-19: a suggested new protocol for early management. Pharmacol Res 157:104874","journal-title":"Pharmacol Res"},{"issue":"09","key":"7822_CR41","doi-asserted-by":"publisher","first-page":"982","DOI":"10.3855\/jidc.13274","volume":"14","author":"JM Calder\u00f3n","year":"2020","unstructured":"Calder\u00f3n JM et al (2020) Nitazoxanide against COVID-19 in three explorative scenarios. J Infect Dev Ctries 14(09):982\u2013986","journal-title":"J Infect Dev Ctries"},{"key":"7822_CR42","doi-asserted-by":"crossref","unstructured":"Rocco PRM, Silva PL, Cruz FF, Melo-Junior MAC, Tierno PFGMM, Moura MA, De Oliveira LFG, Lima CC, Dos Santos EA, Junior WF, Fernandes APSM, Franchini KG, Magri E, de Moraes NF, Gon\u00e7alves JMJ, Carbonieri MN,\nDos Santos IS, Paes NF, Maciel PVM, Rocha RP, de Carvalho AF, Alves PA, Proen\u00e7a-M\u00f3dena JL, Cordeiro AT, Trivella DBB, Marques RE, Luiz RR, Pelosi P, Lapa E Silva JR (2021) SARITA-2 investigators. Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial. Eur Respir J 58(1):2003725","DOI":"10.1183\/13993003.03725-2020"},{"issue":"1","key":"7822_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13063-020-04448-2","volume":"21","author":"JM Calder\u00f3n","year":"2020","unstructured":"Calder\u00f3n JM, Zer\u00f3n HM, Padmanabhan S (2020) Treatment with Hydroxychloroquine vs Hydroxychloroquine+ Nitazoxanide in COVID-19 patients with risk factors for poor prognosis: a structured summary of a study protocol for a randomised controlled trial. Trials 21(1):1\u20133","journal-title":"Trials"},{"issue":"7","key":"7822_CR44","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.3390\/cells9071619","volume":"9","author":"M Bello-Perez","year":"2020","unstructured":"Bello-Perez M et al (2020) Canonical and noncanonical autophagy as potential targets for COVID-19. Cells 9(7):1619","journal-title":"Cells"},{"issue":"1","key":"7822_CR45","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3390\/antiox10010102","volume":"10","author":"F Pietrocola","year":"2021","unstructured":"Pietrocola F, Pedro B-S, Manuel J (2021) Targeting autophagy to counteract obesity-associated oxidative stress. Antioxidants 10(1):102","journal-title":"Antioxidants"},{"issue":"3","key":"7822_CR46","first-page":"675","volume":"166","author":"N Hemmat","year":"2021","unstructured":"Hemmat N et al (2021) The roles of signaling pathways in SARS-CoV-2 infection; lessons learned from SARS-CoV and MERS-CoV. Adv Virol 166(3):675\u2013696","journal-title":"Adv Virol"},{"issue":"4","key":"7822_CR47","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1007\/s10753-019-00994-3","volume":"42","author":"J Shou","year":"2019","unstructured":"Shou J et al (2019) Tizoxanide inhibits inflammation in LPS-activated RAW264 7 macrophages via the suppression of NF-\u03baB and MAPK activation. Inflammation 42(4):1336\u20131349","journal-title":"Inflammation"},{"key":"7822_CR48","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02737-2020","author":"Y Tang","year":"2021","unstructured":"Tang Y, Kwiatkowski DJ, Henske EP (2021) mTORC1 hyperactivation in lymphangioleiomyomatosis leads to ACE2 upregulation in type II pneumocytes: implications for COVID-19. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.02737-2020","journal-title":"Eur Respir J"},{"key":"7822_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.619730","author":"Y Wang","year":"2020","unstructured":"Wang Y et al (2020) AMPK\/mTOR signaling in autophagy regulation during cisplatin-induced acute kidney injury. Front Physiol. https:\/\/doi.org\/10.3389\/fphys.2020.619730","journal-title":"Front Physiol"},{"issue":"5","key":"7822_CR50","doi-asserted-by":"publisher","first-page":"e1002691","DOI":"10.1371\/journal.ppat.1002691","volume":"8","author":"KK Lam","year":"2012","unstructured":"Lam KK et al (2012) Nitazoxanide stimulates autophagy and inhibits mTORC1 signaling and intracellular proliferation of Mycobacterium tuberculosis. PLoS Pathog 8(5):e1002691","journal-title":"PLoS Pathog"},{"issue":"Suppl 1","key":"7822_CR51","doi-asserted-by":"publisher","first-page":"i104","DOI":"10.1136\/ard.2010.140145","volume":"70","author":"SI Grivennikov","year":"2011","unstructured":"Grivennikov SI, Karin M (2011) Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis 70(Suppl 1):i104\u2013i108","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"7822_CR52","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1002\/jmv.26589","volume":"93","author":"B Kerget","year":"2021","unstructured":"Kerget B et al (2021) Evaluation of alpha defensin, IL-1 receptor antagonist, and IL-18 levels in COVID-19 patients with macrophage activation syndrome and acute respiratory distress syndrome. J Med Virol 93(4):2090\u20132098","journal-title":"J Med Virol"},{"issue":"1","key":"7822_CR53","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jaci.2020.09.018","volume":"147","author":"JM Galv\u00e1n-Rom\u00e1n","year":"2021","unstructured":"Galv\u00e1n-Rom\u00e1n JM et al (2021) IL-6 serum levels predict severity and response to tocilizumab in COVID-19: an observational study. J Allergy Clin Immunol 147(1):72-80. e8","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"7822_CR54","doi-asserted-by":"publisher","first-page":"L35","DOI":"10.1152\/ajplung.00170.2020","volume":"319","author":"PR Martins-Filho","year":"2020","unstructured":"Martins-Filho PR, Barreto-Alves JA, Fakhouri R (2020) Potential role for nitazoxanide in treating SARS-CoV-2 infection. Am J Physiol-Lung Cell Mol Physiol 319(1):L35\u2013L36","journal-title":"Am J Physiol-Lung Cell Mol Physiol"},{"issue":"1","key":"7822_CR55","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.intimp.2012.03.002","volume":"13","author":"SK Hong","year":"2012","unstructured":"Hong SK et al (2012) Nitazoxanide suppresses IL-6 production in LPS-stimulated mouse macrophages and TG-injected mice. Int Immunopharmacol 13(1):23\u201327","journal-title":"Int Immunopharmacol"},{"issue":"10","key":"7822_CR56","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1161\/CIRCRESAHA.120.317015","volume":"126","author":"M Gheblawi","year":"2020","unstructured":"Gheblawi M et al (2020) Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2. Circ Res 126(10):1456\u20131474","journal-title":"Circ Res"},{"issue":"6","key":"7822_CR57","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1007\/s10930-020-09935-8","volume":"39","author":"S Suhail","year":"2020","unstructured":"Suhail S et al (2020) Role of oxidative stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) infection: a review. Protein J 39(6):644\u2013656","journal-title":"Protein J"},{"key":"7822_CR58","first-page":"17","volume":"13","author":"TH Abd El-Aziz","year":"2014","unstructured":"Abd El-Aziz TH et al (2014) Effect of Egyptian propolis on lipid profile and oxidative status in comparison with nitazoxanide in immunosuppressed rats infected with Cryptosporidium spp. Glob Vet 13:17\u201327","journal-title":"Glob Vet"},{"issue":"1","key":"7822_CR59","doi-asserted-by":"publisher","first-page":"015001","DOI":"10.1088\/1478-3975\/8\/1\/015001","volume":"8","author":"PC Davies","year":"2011","unstructured":"Davies PC, Lineweaver CH (2011) Cancer tumors as Metazoa 1.0: tapping genes of ancient ancestors. Phys Biol 8(1):015001","journal-title":"Phys Biol"},{"key":"7822_CR60","doi-asserted-by":"publisher","first-page":"111430","DOI":"10.1016\/j.biopha.2021.111430","volume":"138","author":"A Liskova","year":"2021","unstructured":"Liskova A et al (2021) Flavonoids against the SARS-CoV-2 induced inflammatory storm. Biomed Pharmacother 138:111430","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"7822_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00018-022-04246-w","volume":"79","author":"A Riccio","year":"2022","unstructured":"Riccio A et al (2022) Impairment of SARS-CoV-2 spike glycoprotein maturation and fusion activity by nitazoxanide: an effect independent of spike variants emergence. Cell Mol Life Sci 79(5):1\u201321","journal-title":"Cell Mol Life Sci"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-022-07822-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-022-07822-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-022-07822-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T12:39:58Z","timestamp":1667133598000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-022-07822-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,12]]},"references-count":61,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["7822"],"URL":"https:\/\/doi.org\/10.1007\/s11033-022-07822-2","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,12]]},"assertion":[{"value":"13 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}